PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology
Manuscript NO: 64748
Title: Can dietary flavonoids be useful in the personalized treatment of colorectal cancer?

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind
Reviewer’s code: 03471268
Position: Editorial Board
Academic degree: PhD
Professional title: Associate Professor
Reviewer’s Country/Territory: Japan
Author’s Country/Territory: Portugal
Manuscript submission date: 2021-02-23
Reviewer chosen by: Ya-Juan Ma
Reviewer accepted review: 2021-03-31 01:04
Reviewer performed review: 2021-04-05 16:07
Review time: 5 Days and 15 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>Grade B: Very good</th>
<th>Grade C: Good</th>
<th>Grade D: Fair</th>
<th>Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>Grade A: Priority publishing</td>
<td>Grade B: Minor language polishing</td>
<td>Grade C: A great deal of language polishing</td>
<td>Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>Accept (High priority)</td>
<td>Accept (General priority)</td>
<td>Minor revision</td>
<td>Major revision</td>
<td>Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>Yes</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS
This is an interesting article in which the authors show us the role of dietary flavonoids in the personalised treatment of colorectal cancer. It is well written, but some issue I raised should be addressed as followings: 1. In the context of background knowledge and CRC treatment, the narrative could be developed in terms of the pathogenesis and relevant influencing factors of CRD and existing treatment strategies, and what are the respective strengths and weaknesses of the drugs available in treatment? A table is desirable and a logical narrative rather than an item-by-item presentation is needed. 2. Can there be additional information on whether the subtypes of flavonoids differ between vegetables and fruits? 3. Are there any links between the CRC isoforms and the six subclasses of flavonoids? And about the potential therapeutic mechanisms of these flavonoids could be illustrated graphically. 4. It is well known that drug therapy without dosage is not justified and although foods containing flavonoids may be beneficial in the treatment of colorectal cancer, do the flavonoid content of different foods vary? Is the more the better or otherwise? Is there a daily limit on the amount of different types of food that can be consumed daily? 5. The format of the citations is not uniform, for example “The aim of EGFR inhibitors is to prevent EGFR activation of both MAPK and PI3K/AKT pathways but, downstream activating mutations such as in RAS, BRAF or PI3K, override the effect of the drug rendering the tumor resistant to anti-EGFR treatment (DeStefanis 2019).” in part of CRC treatment. 6. “chemotherapeutic drugs, use 5-FU and address the involvement of p53 in the response, due to the key role of p53 in apoptosis induction and treatment sensitivity[30, 34-39].” in part of Combination of flavonoids plus chemotherapeutic agents, the format of the citation here is inappropriate.
7. Some abbreviations are not explained when they first appear.